Abstract
This study aims to provide an accessible and dynamic estimate method to project the Covid-19 trend and hopefully it will help inform policymakers to allocate the needed medical equipment and supplies for saving more lives. A set of newly developed Pandemic Projection Measures (PPM) had been successfully applied to project daily new cases across countries. During the development, numerous trial and error iterations had been performed and then improved with live data. The procedures and computations for the PPM including Uphill Index (UHI), Downhill Indices (DHI), and Error Band Projection (EBP) estimates were explained and discussed along with graphical projections. The PPM was computed with daily live data for the USA, four U.S. states (Illinois, Massachusetts, New Jersey, and New York), France, Italy, Spain, Germany, and China. The results indicated that with the PPM estimations, the daily projections for the future trend were robust to reflect the most plausibility, since the PPM can be updated frequently. With the most up-to-date predictions, governments should be able to monitor the values of UHI and DHI for making a better decision for “flattening the curve”. Based on the empirical data, policymakers should pay more attentions for the following two scenarios: a) When expecting an apex of the outbreak, the UHI is higher than 1.20; and b) After passing a peak day, the DHI is still larger than 0.925. The applications of the PPM estimates are not designed for a one-time projection rather than updated frequently to improve the prediction precisions. With the same concepts from the PPM computations, the peak day and the number of new deaths could be predictable if more data are collected. Like many country leaders saying, “We will win the battle of coronavirus pandemic”, the author hopes to use this easily applicable estimate method to save more lives and to win. The results, currently presented with the data on April 16 and 17, 2020, were only used to explain how to apply the PPM estimates for predictions. The outdated results should not be used to compared with today’s outbreak trend.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author received no direct funding for this research.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study only used publicly available data and did not involve any experiments for human subjects.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data used in this study are available for download
